Back to Search Start Over

Management of low-risk papillary thyroid cancer. Minimally-invasive treatments dictate a further paradigm shift?

Authors :
Papini, E.
Guglielmi, R.
Novizio, R.
Pontecorvi, A.
Durante, C.
Source :
Endocrine (1355008X); Aug2024, Vol. 85 Issue 2, p584-592, 9p
Publication Year :
2024

Abstract

Background: Current management options for PTMC include lobo-isthmectomy and active surveillance (AS). Recently, ultrasound-guided minimally invasive procedures (MITs) are offered as a nonsurgical therapy for PTMC because they do not require hospitalization and general anaesthesia, and do not result in loss of thyroid function or cosmetic damage. MITs are reported to consistently provide, mostly in large retrospective series of patients, a rapid, safe, and cost-effective way to eradicate low-risk thyroid malignancies. However, conclusive data from well-conducted prospective studies on the histologically-proven completeness of tumor ablation and the long-term clinical advantages versus AS are still lacking. Objectives: This study aimed to evaluate the efficacy and safety of ultrasound-guided minimally invasive treatments (MITs) for PTMC in comparison to traditional surgical methods and active surveillance, and to assess their role in current clinical practice. Methods: A structured literature review was conducted using keywords related to PTMC, MIT, and comparative techniques. Studies were evaluated based on treatment modality, patient selection, follow-up duration, complication rates, and clinical outcomes. Results: MITs have shown promising results in the management of PTMC. These treatments offer several advantages over surgery, such as reduced use of surgical resources, lower costs, minimal work disruption, and fewer major complications. However, there are still limitations, including the need for long-term surveillance and the potential risk of incomplete tumor ablation. Conclusions: MITs represent a promising non-surgical option for managing low-risk PTMC, especially for patients ineligible for or refusing surgery. Despite favorable outcomes, more robust prospective data are needed to confirm their long-term benefits and completeness of tumor ablation. Interdisciplinary discussions and thorough patient education on the advantages and limitations of MITs are crucial for informed decision-making. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
1355008X
Volume :
85
Issue :
2
Database :
Complementary Index
Journal :
Endocrine (1355008X)
Publication Type :
Academic Journal
Accession number :
178777646
Full Text :
https://doi.org/10.1007/s12020-024-03864-7